Long-Term Care Membership on the Presence of Elevated Bacterial Burden in Patients Wounds
VALLEY STREAM, NY and TORONTO, March 9, 2021 /PRNewswire/ - MolecuLight Inc., the leader in fluorescence imaging for point-of-care detection of wounds containing elevated bacterial loads, announces the availability of its MolecuLight
i:
X® platform to 650 long-term healthcare facilities in the US through its new commercial arrangement with Synergy HealthCare Alliance, LLC.
Synergy HealthCare Alliance, LLC is a Group Purchasing Organization (GPO) specializing in sub-acute and long-term care. Synergy provides its member healthcare organizations with access to its superior contract portfolio and unparalleled pricing agreements. MolecuLight is now a registered partner and its
Today, The Veterans Action Council (VAC) is Announcing the Publication of Their Green Paper
News provided by
Share this article
CARLSBAD, Calif., March 9, 2021 /PRNewswire/ The
Green Paper outlines significant and key concerns within the medical cannabis community, and what the Veterans Action Council feel are potential remedies, particularly as they relate to our Veterans. As Veterans of the United States Armed Forces, we call on the Veterans Health Administration (VHA) to fully recognize cannabis as a viable treatment option for US Veterans.
Multiple attempts have been made to resolve the inability of Veterans to incorporate cannabis into their official treatment plans. Every attempt made to address our concerns has been sabotaged at the federal level. The VHA must take action on this issue. The fact is, Veterans are self-medicating with cannabis and other substances. Veteran s report turning to cannabis after pharmaceutical options provided by the VHA - some of which
1.2 Analysis Framework: Core Value
1.3 Research Methodology: Five Steps Toward Success
1.4 Key Findings of Technology Breakthrough Driving Sepsis Diagnosis
2. Technology Snapshot
2.2 Types of Sepsis Diagnosis Tests
3. Understanding Sepsis
3.2 Unmet Needs in Sepsis Management
4. Clinical Trials and Patent Landscape for Sepsis Diagnosis
4.1 Outlook of Sepsis Diagnosis Clinical Trials
4.2 Industry Sponsored Sepsis-Diagnostic Test Clinical Trials
4.3 Non-industry Sponsored Sepsis-Diagnostic Test Clinical Trials in Europe
4.4 Non-industry Sponsored Sepsis-Diagnostic Test Clinical Trials in the Americas, Asia and Rest of the World
4.5 Scholarly Publications Including Patents for Sepsis
5. Rapid Diagnosis of Sepsis
5.1 List of COMPANIES in Sepsis Diagnosis
5.2 The US Is The Biggest Hub For Sepsis Diagnosis
Adverse Event Reporting Software Segment to Grow at Highest CAGR During 2020-2027
Pharmacovigilance and Drug Safety Software Market is expected to reach US$ 292.97 Mn in 2027 from US$ 160.67 Mn in 2019. The market is estimated to grow at a CAGR of 7.6% from 2020 to 2027.
The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth. Factors such as rising incidences of adverse drug reaction (ADR) and globalization of pharmacovigilance have been boosting the market over the years. However, the expensive technology is likely to have a negative impact on the growth of the market in the coming years.
Valo Health Receives $110 Million In Funding From Koch Disruptive Technologies To Close Series B
Valo s CEO To Provide Insights On Programs And Opal Platform At Barclays Global Healthcare Conference
News provided by
Share this article
Share this article
BOSTON, March 9, 2021 /PRNewswire/ Valo Health LLC (Valo), a technology company transforming the drug discovery and development process and seeking to accelerate the creation of life-changing drugs, today announced the final closing of its Series B at $300 million, including a $110 million investment from Koch Disruptive Technologies (KDT). This brings the overall funding of Valo to over $450 million.
With this investment Valo will continue to scale its Opal Computational Platform